Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Farmers Insurance
US Department of Justice
Accenture
US Army
Healthtrust
AstraZeneca
Boehringer Ingelheim
Citi

Generated: July 22, 2018

DrugPatentWatch Database Preview

MOZOBIL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Mozobil, and when can generic versions of Mozobil launch?

Mozobil is a drug marketed by Genzyme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-nine countries.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the plerixafor profile page.
Drug patent expirations by year for MOZOBIL
Generic Entry Opportunity Date for MOZOBIL
Generic Entry Date for MOZOBIL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MOZOBIL
Synonyms for MOZOBIL
078P461
1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA)
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA)
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA)
1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O)
11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane
110078-46-1
155148-31-5
3B1-000393
4CA-1029
A25446
A809618
AB0009909
AB01566900_01
AB1008451
AC-26837
AC1L22ET
AJ-81365
AK-41732
AKOS005266706
Amd 3100
AMD-3100
AMD3100
AMD3100 octahydrochloride
AN-436
ANW-73610
AOB5591
BC623053
BCPP000104
BDBM50035696
bicyclam JM-2987
BRD-K33240821-367-01-8
C28H54N8
CHEBI:125354
CHEMBL18442
CS-0451
CTK8C4952
D08971
D0L5RW
DB06809
FT-0660392
GNA & AMD-3100
GTPL844
HE070541
HE295036
HHA & AMD-3100
HY-10046
I14-9461
J-503718
JM 2987
JM 3100
JM 3100, AMD3100
JM-3100
JM3100
KS-00000OBY
L000104
LS-187299
MFCD05662218
MolPort-009-019-417
Mozobil (TN)
NCGC00165722-01
NCGC00165722-02
Plerixafor
plerixafor (amd3100)
Plerixafor (INN/USAN)
Plerixafor (JAN/USAN/INN)
Plerixafor 8HCl
Plerixafor hcl
Plerixafor hydrochloride
Plerixafor(AMD3100)
RL00426
S-7677
s8030
S915P5499N
SC-21932
SCHEMBL19038
SDZ SID 791
SID791
SR-01000941593
SR-01000941593-1
ST2414835
TC-162355
UNII-S915P5499N
YIQPUIGJQJDJOS-UHFFFAOYSA-N
Z2196779619
ZINC22443609

US Patents and Regulatory Information for MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for MOZOBIL
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 24 mg/1.2 mL vials (20 mg/mL) ➤ Subscribe ➤ Try a Free Trial

Non-Orange Book US Patents for MOZOBIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity ➤ Try a Free Trial
7,169,750 Methods to mobilize progenitor/stem cells ➤ Try a Free Trial
7,935,692 Methods to mobilize progenitor/stem cells ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for MOZOBIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00052 Denmark ➤ Try a Free Trial
C/GB12/031 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804
2012011 Lithuania ➤ Try a Free Trial PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
2012 00026 Denmark ➤ Try a Free Trial
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Healthtrust
US Department of Justice
Medtronic
Chubb
Merck
AstraZeneca
Chinese Patent Office
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.